Navigation Links
HSA Plans Gain Popularity as Premium Costs Rise
Date:9/26/2007

Hewitt Data Good News for Future Cost Controls, Says NCPA's Goodman

DALLAS, Sept. 26 /PRNewswire-USNewswire/ -- About half of all employers are expected to soon offer Health Savings Account (HSA) plans to their employees. This projection offers the best hope for restraining runaway health care costs, according to John Goodman, president of the National Center for Policy Analysis (NCPA).

"The best way to control health care costs is to put patients in control of more of their health care dollars," said Goodman. "The increasing popularity of HSAs is a result of managed care's failure."

According to a report released this week by Hewitt and Associates, a global human resources company, "account-based plans are gaining traction by employers as a way to control costs." Hewitt's research found that more than 20 percent of companies offer, or plan to offer, a high-deductible health plan with an HSA by the end of this year and almost half are considering offering one at a future date. While just 3 percent of employees elected these plans last year, most companies anticipate that enrollment will grow to 20 percent in 5 years.

A major factor in the movement towards consumer-directed health care plans is the ever-increasing premium rates. While employers enjoyed a nine-year low in health care cost rate increases this year -- a 5.3 percent average increase, down from 7.9 percent in 2006 -- that is expected to change in 2008. Premiums are expected to rise by an average of 8.7 percent in 2008. For example:

-- Premiums for traditional indemnity plans increased 9.1 percent in

2007 and are expected to increase 9.0 percent in 2008;

-- Premiums for HMOs increased 8.7 percent in 2007 and are expected to

increase 9.0 in 2008;

-- Premiums for point-of-service (POS) plans increased 3.9 percent in

2007 and are expected to increase 8.5 percent in 2008;

-- Premiums for preferred provider organizations
'/>"/>

SOURCE National Center for Policy Analysis
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. France plans to protects its citizens from bird flu
2. MSI puts on hold plans for operations in Chennai
3. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
4. Wockhardt Group Plans Hospital In Delhi By End-2007
5. Alberta’s New Reform Plans In Health Care Secto
6. Blue Cross Signs Up 110,000 Minnesotans For Part D Medicare Plans
7. Little Clinic LLC Plans Super Medical Clinics in Publix Super Markets
8. Medicare Drug Plans Are Onerous and Restrictive
9. Rajasthan Plans To Run Christian Institutions
10. Britains Bird Flu Contingency Plans Faces Criticism
11. Coraki Community Wants To Know About the Plans for the Campbell Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:MU research team makes progress toward 'printing' organs 2Health News:MU research team makes progress toward 'printing' organs 3Health News:Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: 2Health News:Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: 3Health News:Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: 4Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 2Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 3Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 4Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 5Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 6Health News:'AHF/India Cares' Provides Second-line AIDS Drugs to Activists in India 2Health News:'AHF/India Cares' Provides Second-line AIDS Drugs to Activists in India 3Health News:NIH grant advances dentistry school's work on psychosocial stress 2Health News:NIH grant advances dentistry school's work on psychosocial stress 3Health News:Energy Drinks Could Pose Blood Pressure Risks 2
Breaking Medicine Technology:Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 2Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 3Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 4Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 5Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 6Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 7Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 8Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis 9Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8PCAST Members Advise President on Future of Healthcare Energy 55024 1PCAST Members Advise President on Future of Healthcare Energy 55024 2Right Match of Drug Doctor Can Boost Reflux Outcomes 55021 1Right Match of Drug Doctor Can Boost Reflux Outcomes 55021 2Right Match of Drug Doctor Can Boost Reflux Outcomes 55021 3Chemist+Druggist Reveals Frontline NHS Staff Wont Get Swine Flu Vaccine 13647 1Chemist+Druggist Reveals Frontline NHS Staff Wont Get Swine Flu Vaccine 13647 2
Other Medicine Technology:Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 3Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 4Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 5Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 6Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 7Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 8Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 9Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 10Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 11Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 12